Growth patterns of colorectal cancer liver metastases and their impact on prognosis: a systematic review

Carlos Fernández Moro,^{1,2} Béla Bozóky,² Marco Gerling^{3,4}

To cite: Fernández Moro C, Bozóky B, Gerling M. Growth patterns of colorectal cancer liver metastases and their impact on prognosis: a systematic review. *BMJ Open Gastro* 2018;**5**:e000217. doi:10.1136/bmjgast-2018-000217

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjgast-2018-000217>).

Received 7 May 2018
Revised 7 June 2018
Accepted 17 June 2018

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Division of Pathology, Department of Laboratory Medicine (LabMed), Karolinska Institute, Stockholm, Sweden

²Department of Clinical Pathology/Cytology, Karolinska University Hospital, Stockholm, Sweden

³Department of Biosciences and Nutrition, NEO, Karolinska Institutet, Huddinge, Sweden

⁴Tema Cancer, Karolinska University Hospital, Solna, Sweden

Correspondence to

Dr. Marco Gerling;
marco.gerling@ki.se

ABSTRACT

Background Colorectal cancer liver metastases (CRLM) grow in distinct histological patterns that have been associated with outcome after surgical resection. We conducted a systematic review to evaluate the frequency of different CRLM growth patterns and their impact on prognosis.

Methods We searched Embase and MEDLINE databases from inception to 1 December 2017 to identify studies that reported CRLM growth pattern histopathology, their frequencies, and/or data related to outcome.

Results We included a total of 23 studies (2432 patients with CRLM) published between 1991 and 2017. There were variations in the terminology used to describe the growth patterns as well as in their histopathological definitions. A 'desmoplastic' pattern was most frequently considered, followed by 'pushing' and 'replacement' patterns. Data supported the presence of both intralesional and interlesional heterogeneity. There were no differences in growth pattern distribution stratified by chemotherapy. While heterogeneity of histopathology assessment precluded formal meta-analysis, the majority of articles found favourable outcomes for desmoplastic and unfavourable outcomes for replacement CRLM, independently of when the study was conducted.

Conclusions The results suggest that CRLM growth patterns may have prognostic potential and that they may be considered for standardised routine histopathological reporting. Further understanding of the different growth patterns may provide important insights into the biological mechanisms that underlie metastatic growth in the liver.

INTRODUCTION

Colorectal cancer (CRC) is one of the most frequent malignancies worldwide.¹ Multimodal stage-dependent therapy combining surgery and chemoradiotherapy achieves good long-term survival in patients without distant metastases.² However, approximately half of all patients with CRC develop metastases during the course of their disease, at which point survival rates drop markedly.³ The liver is the organ in which CRC metastases are most frequently found.⁴ In contrast to most other cancer types, surgical resections of colorectal cancer liver metastases

(CRLM) are routinely performed.⁵ Unfortunately, despite advances in surgical techniques and neoadjuvant chemotherapy, the management of CRLM remains a formidable challenge, as evidenced by the generally poor long-term survival rates.⁶

In primary CRC, the presence of different histological growth patterns is well known: Jass *et al* described an 'infiltrating' pattern, in which cancer cells invade diffusely into surrounding tissue, in contrast to a 'pushing' or 'expanding' growth pattern, in which the tumour border is clearly demarcated.⁷ This assessment of the tumour border has been well established in diagnostic pathology,⁸ and may serve for prognostic stratification, as primary CRCs with a predominantly 'pushing' border are associated with a more favourable outcome.^{9 10}

With the increasing frequency of CRLM resections, the histomorphology of the metastatic front in liver metastases has become routinely accessible and several different CRLM growth patterns have been described: a 'desmoplastic' or 'encapsulated' pattern, in which the tumour cells are separated from the liver parenchyma by a rim of fibrotic stroma, is distinguished from a 'pushing' or 'expansive' pattern, in which the liver plates adjacent to the metastases are flattened, while intervening fibrotic tissue is absent. A further pattern is termed 'invasive' or 'replacement'; in this case, the tumour cells infiltrate along the liver cell plates, replace hepatocytes and co-opt the sinusoidal stromal scaffold.^{11 12} In addition, overlaps of these patterns have been observed.^{13 14}

Several studies have suggested that these distinct growth patterns are associated with differences in tumour recurrence and overall survival (OS).^{14–16} However, cohorts were of limited size, terminology and histological criteria were heterogeneous, and the morphology of the CRLM tumour border is not routinely reported in clinical practice.¹⁷

Systematic work by an international multidisciplinary team has recently resulted in the first consensus guidelines for scoring CRLM growth patterns.¹⁸ In the suggested guidelines, the authors define three main growth patterns, *desmoplastic*, *replacement*, and *pushing*. By applying this classification to a validation cohort of 374 patients, they find superior survival in the group with predominantly desmoplastic growth pattern, compared with the replacement type. Their work highlights that it is possible to systematise CRLM growth patterns in a reproducible and clinically valuable way.

From a tumour biology perspective, the modes of metastatic growth in the liver are of paramount interest. Recent studies have identified the local microenvironment as a major determinant of tumour aggressiveness in various cancer types including CRC.^{19–23} In each CRLM growth pattern, metastasised cancer cells interact in particular ways with different host cells such as hepatocytes, Ito cells, and endothelial cells, and are thus embedded in diverse biological microenvironments with hitherto unidentified impact on cancer cell behaviour. Hence, a deeper understanding of the different growth patterns holds potential for deciphering important mechanistic aspects of metastatic tumour progression.

We conducted this systematic review of the literature on CRLM growth patterns to systematically analyse variations in their nomenclature and to evaluate their reported frequencies as well as their impact on patient survival. Finally, we highlight recent functional evidence on the mechanistic underpinnings of this important clinicopathological phenomenon.

METHODS

Literature search and selection criteria

We performed a systematic search for published studies on growth patterns in CRLM as of 1 December 2017 in Embase and MEDLINE databases. The search strings (online supplementary figures 1 and 2) were designed to find articles on liver metastases from adenocarcinomas of the colon or rectum that included a histological evaluation of the tumour border and assessed the growth pattern.

Additional searches were performed based on the lists of references in the eligible studies. Inclusion criteria for abstract review were defined as follows and judged independently by two reviewers (MG and CFM): (1) report on sporadic colon and/or rectum adenocarcinoma; (2) report on liver metastases; (3) histological assessment of the tumour border, either explicitly stated or implied (eg, by mentioning immunohistochemistry on CRLM sections); (4) species is human. Exclusion criteria were: (1) language other than English, Spanish, German or Swedish; (2) article is a case report; (3) article is a review.

After independent evaluation, MG and CFM discussed those articles for which there was disagreement on their inclusion. If no agreement was reached, BB was consulted.

This systematic review was not preregistered.

Data extraction

The full texts of potentially eligible articles were acquired by MG, assessed independently by and finally discussed between MG and CFM to reach agreement on their final inclusion. In the case of overlapping cohorts, the article with the largest sample size was included; if the exact same cohort was reported more than once (as identified by the number of patients, clinical institution, and dates of sample collection), the most recent publication was included. If CRLM growth patterns were assessed histologically, but not quantified, the corresponding author(s) were contacted by email and asked to share the following information: histopathological definition/growth pattern criteria, absolute frequencies, and available survival data. Requests were also made in cases of potential overlap of similar, but not identical, study cohorts (according to date, size, and reported data). If there was no reply within 1 week, an additional email was sent; in case of no response within a total of 2 weeks, the request was considered to have failed and the decision on inclusion was made jointly by CFM and MG; if no agreement could be reached, BB was consulted.

Estimates of internal study validity were recorded using a modified version of the *Quality Assessment of Diagnostic Accuracy Studies* criteria.²⁴ Based on these data, *Risk of Bias* was assessed using an adapted version of the Cochrane Collaboration's tool for assessing Risk of Bias²⁵; 'performance bias' and 'allocation bias' were not assessed as the analysed studies were non-interventional.

Data handling

GraphPad Prism (V.6.0g) was used for data analysis. For word clustering, growth pattern terminology was extracted from all eligible studies and groups of terms were inferred by the descriptions of the histological patterns (eg, in a study where the term 'sinusoidal' was used to describe a pattern in which tumour cells replace hepatocytes, this was considered to represent the 'replacement' pattern). The absolute frequency of each term was calculated and the terms were displayed in a word clustering diagram with a proportional font size.

RESULTS

Figure 1 shows the study flow diagram according to the *Preferred Reporting Items for Systematic Reviews and Meta-Analyses* criteria.²⁶ The search strategy identified a total of 2473 articles, of which 2368 were excluded after abstract review. Full texts were acquired for 105 articles and after full text review, 23 studies reporting data on a total of 2432 patients were considered eligible.^{11–14 18 27–44}

Table 1 presents the eligible studies included for systematic review and the clinicopathological characteristics of the cohorts; online supplementary figure 3 presents data on the risk of bias.

Terminology of CRLM growth patterns

Although in general three major patterns were discernible across the studies, the terminology used to describe

Figure 1 Study flow diagram according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. One study¹⁵ was included specifically for outcome data, as it reported the outcome for a cohort published in a more recent article¹³; this study was excluded due to overlapping cohort from the main series. Another study²⁷ included two independent patient cohorts that were reported separately; this study is counted as one item.

different growth patterns varied markedly (illustrated in figure 2). The most frequently used single term to describe the presence of fibrotic tissue separating tumour and liver cells was ‘desmoplastic’ (27% of all studies), but expressions referring to ‘capsule’ (such as ‘encapsulated’ or ‘pseudocapsule’) were cumulatively more frequent (54.5%). The most frequently used term to describe a pattern in which tumour cells infiltrate along the liver cell plates and replace the hepatocytes was ‘replacement’ (27.3%), followed by ‘infiltrative’ (22.7%). The third pattern, in which liver cell plates surrounding the tumour appear flattened (often referred to as ‘compressed’), while intervening fibrotic tissue is absent, was most frequently described as ‘pushing’ (31.8%), followed by ‘expansive’ (22.7%). Throughout the remainder of this article, we employ the most frequently used terms, ‘desmoplastic’, ‘replacement’, and ‘pushing’, adhering to the consensus guidelines.¹⁸

Classification schemes and histopathological criteria for growth pattern reporting

Not all studies considered all three major patterns. Overall, the desmoplastic pattern was considered most frequently (in 21 out of 23 studies), while the replacement

and pushing patterns were described less often (both in 14 out of 23 studies; figure 3A). A total of 11 studies distinguished between two growth patterns, while 11 studies used a three-tier, and one study a four-tier classification system (figure 3B). The consensus paper specifically discusses two further rare growth patterns, ‘sinusoidal’ and ‘portal’,¹⁸ which are not systematically used in the literature and for the sake of practicability will not be considered further here.

The exact definitions of the histopathological criteria varied substantially (online supplementary table 1). For example, describing the desmoplastic pattern, some definitions required the metastases to be ‘completely surrounded by fibrous tissue’³⁸ or to be of a certain thickness that varied between studies,^{29 32} while other definitions were less specific and based on the presence of a ‘fibrotic capsule’.^{30 42 44}

Four studies reported the presence or absence of a fibrotic capsule as a feature separate from either the replacement or pushing growth patterns (table 1). In general, a heterogeneous picture of histopathological definitions and classification schemes became evident.

Table 1 Overview of eligible studies included

Study	Title	Publication year	Time period	Location	Male	Female	Primary in colon	Primary in rectum	Synchronous CRLM	Metachronous CRLM	Desmoplastic CRLM (%)	Pushing CRLM (%)	Replacement CRLM (%)	Mixed CRLM (%)	Capsule independent	Outcome assessed	Prooperative chemo
van Dam <i>et al</i> ¹⁸	International consensus guidelines for scoring the histopathological growth patterns of liver metastasis	2017	2000–2015	Department of Surgical Oncology, Erasmus MC Cancer Institute (Rotterdam, The Netherlands)	241	133	204	170	243 (defined as <1 year)	131	49	3	47	1, excluded from survival analysis; >50% predominance was considered sufficient	N	Y	>44% of patients
Frentzas <i>et al</i> ²⁷ London cohort	Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases	2016	2006–2012	The Royal Marsden Hospital (RM), London, UK	21	12	12	21	NA	NA	52.5	1.7	45.8	NA	N	Y	All bev+chemo
Frentzas <i>et al</i> ²⁷ Montréal cohort	Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases	2016	2008–2014	McGill University Health Centre (MUHC), Montréal, Canada	35	24	39	20	NA	NA	51.6	3.1	45.3	NA	N	Y	All bev+chemo
Sriwardana <i>et al</i> ⁸	Biological and prognostic significance of the morphological types and vascular patterns in colorectal liver metastases (CRLM) looking beyond the tumor margin	2016	1998–2008	Royal Free Hospital, London, UK	18	8	18	6	7	19	43.3	NA	43.3	10	N	Y	N
Serrablo <i>et al</i> ²⁹	Impact of novel histopathological factors on the outcomes of liver surgery for colorectal cancer metastases	2016	2004–2010	NA, Spain and/ or Italy	NA	NA	NA	NA	NA	NA	17	52.3	46.3	NA	Y	Y	Reported separately
Edisen <i>et al</i> ¹³	Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab	2015 (print 2016)	2007–2011	Rigshospitalet, Copenhagen, Denmark	146	91	162	75	146	91	29.5	37.1	14.8	18.6	N	N (for same cohort in ref 15)	Reported separately
Brunner <i>et al</i> ³⁰	Prognosis according to histochemical analysis of liver metastases removed at liver resection	2014	2004–2010	Regensburg, Germany	118	83	119	82	NA	NA	37.8	NA	NA	NA	N	Y	Reported separately
Pinheiro <i>et al</i> ³¹	Tumor growth pattern as predictor of colorectal liver metastasis recurrence	2014	2000–2009	NA, likely Sao Paulo, Brazil	50	41	NA	NA	43	48	NA	40.7	59.3	NA	N	Y	Reported separately
Wiggins <i>et al</i> ³²	Extended pathology reporting of resection specimens of colorectal liver metastases: the significance of a tumour pseudocapsule	2012 (print 2013)	2010–2011	Derford Hospital, UK	40	26	NA	NA	38	28	41.5	NA	NA	NA	N	Y	Mixed

Continued

Table 1 Continued

Study	Title	Publication year	Time period	Location	Male	Female	Primary in colon	Primary in rectum	Synchronous CRLM	Metachronous CRLM	Desmoplastic CRLM (%)	Pushing CRLM (%)	Replacement CRLM (%)	Mixed CRLM (%)	Capsule independent	Outcome assessed	Preoperative chemo
Nyström <i>et al</i> ²³	Liver-metastatic potential of colorectal cancer is related to the stromal composition of the tumour	2012	1998–2009	Västerbotten County, Sweden	25	23	29	18	NA	NA	45.8	52.1	NA	NA	N	Y	Mixed
Van Den Eynden <i>et al</i> ¹⁴	The histological growth pattern of colorectal cancer liver metastases has prognostic value	2012	1997–2005	Royal Hallamshire Hospital, Sheffield, UK	NA	NA	104	91	101	98	34.6	15.6	27.8	17.6	N	Y	NA
Rajaganesan <i>et al</i> ¹⁴	Biological characteristics and behaviour of putatively curatively resected colorectal liver metastases	2007 (print 2008)	1993–2004	St James's University Hospital, Leeds, UK	60	49	NA	NA	19	90	34.8	NA	NA	NA	N	Y	Untreated group reported in ref 46
Stessels <i>et al</i> ¹⁵	Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia	2004	NA	General Hospital Sint-Augustinus and of the University of the Hospital of Antwerp, Belgium	NA	NA	NA	NA	NA	NA	50	17.9	32.1	NA	N	N	NA
Terayama <i>et al</i> ¹⁶	Peritumoral rim enhancement of liver metastases: hemodynamics observed on single-level dynamic CT during hepatic arteriography and histopathologic correlation	2002	NA	Kanazawa University School of Medicine, Japan	24	5	NA	NA	NA	NA	10.5	NA	NA	NA	N	N	NA
Yamaguchi <i>et al</i> ¹⁷	Mode of infiltrative growth of colorectal liver metastases is a useful predictor of recurrence after hepatic resection	2002	1981–1998	Nagasaki University School of Medicine, Japan	NA	NA	NA	NA	NA	NA	NA	38.1	61.9	NA	N	Y	NA
Vermeulen <i>et al</i> ¹²	Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia	2001	NA	University Hospital Antwerp and AZ Sint-Augustinus, Belgium	NA	NA	NA	NA	NA	NA	42.3	46.2	11.5	NA	N	N	Excluded
Weber <i>et al</i> ¹⁸	Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases?	2001	1988–1998	Hôpital Universitaire de Haute-pierre, Strasbourg, France	132	89	142	76	90	131	28.5	34.8	65.2	NA	Y	Y	NA

Continued

Table 1 Continued

Study	Title	Publication year	Time period	Location	Male	Female	Primary in colon	Primary in rectum	Synchronous CRLM	Metachronous CRLM	Desmoplastic CRLM (%)	Pushing CRLM (%)	Replacement CRLM (%)	Mixed CRLM (%)	Capsule independent	Outcome assessed	Preoperative chemo
Lunevicius <i>et al</i> ²⁸	Clinicopathological significance of fibrotic capsule formation around liver metastasis from colorectal cancer	2001	1983–1997	Aichi Cancer Center, Japan	NA	NA	NA	NA	NA	NA	20.3	NA	NA	NA	N	Y	NA
Okano <i>et al</i> ⁴⁰	Fibrous pseudocapsule of metastatic liver tumors from colorectal carcinoma: clinicopathologic study of 152 first resection cases	2000	1992–1996	National Cancer Center Hospital, Tokyo, Japan	104	48	NA	NA	46	106	61.1	NA	NA	NA	N	Y	NA
Ambiru <i>et al</i> ⁴¹	Hepatic resection for colorectal metastases: analysis of prognostic factors	1999	1984–1997	Chiba University School of Medicine, Japan	104	62	109	53	71	91	27.9	NA	NA	NA	N	Y	NA
Nagashima <i>et al</i> ⁴¹	Histopathological prognostic factors influencing long-term prognosis after surgical resection for hepatic metastases from colorectal cancer	1999	1981–1994	Tokyo University Hospital, Japan	48	11	NA	NA	24	35	80	91.5	8.5	NA	Y	Y	NA
Terayama <i>et al</i> ⁴²	Histologic growth patterns of metastatic carcinomas of the liver	1996	NA	Kanazawa University School of Medicine, Japan	6	7	13	NA	NA	NA	15.4	76.9	7.7	NA	N	N	NA
Yamamoto <i>et al</i> ⁴³	Pathologic support for limited hepatectomy in the treatment of liver metastases from colorectal cancer	1995	1991–1992	National Cancer Center Hospital, Tokyo, Japan	26	14	27, multiple primaries	12, multiple primaries	8	32	70	NA	NA	NA	N	N	NA
Morino <i>et al</i> ⁴⁴	Clinico-pathological features of liver metastases from colorectal cancer in relation to prognosis	1991	1980–1986	Kyoto University Hospital, Japan	16	13	12	17	11	18	27.6	20.7	34.5	41.4	Y	Y	NA

Clinicopathological data were extracted as specified in the Methods section.
bev, bevacizumab; chemo, conventional cytotoxic chemotherapy; CRLM, colorectal cancer liver metastases; N, no; NA, not available; Y, yes.

Figure 2 Word cluster diagram of colorectal cancer liver metastases growth pattern terminology. Original terms for the histological growth patterns in the literature are shown in a font size proportional to their absolute frequency (n=22 studies, not considering the consensus guidelines¹⁸ as these already reflect a distillate from previous studies). These are grouped and coloured by similarity into 'consensus terms' ('desmoplastic', green; 'pushing', blue; and 'replacement', red). The filled green shape indicates terms related to 'capsule'.

Reported frequencies of CRLM growth patterns

Reported unweighted median frequency for the desmoplastic pattern was 41.7% (range: 10.5%–80%), for the pushing pattern 37.1% (range: 1.7%–91.5%), and for the replacement pattern 43.3% (range: 7.7%–65.2%) (figure 3C).

Reported frequencies of CRLM growth patterns in relation to preoperative chemotherapy

Following current treatment routines, most patients with CRLM will undergo preoperative chemotherapy,⁴⁵ which may impact directly on the growth pattern phenotypes or select for those types possibly resistant to chemotherapy. Thus, we assessed whether studies explicitly reported data on chemo-naïve patients. For articles published in the 1990s, systemic preoperative chemotherapy was unlikely, but given regional and historic differences in treatment regimens that may not have been reported in detail, we included only those studies with explicit statements. We identified two studies in which only patients who had *not* received preoperative chemotherapy were included.^{12 28} In a third study (not included in the eligible studies due to overlap with a more recent report), data for patients without preoperative chemotherapy were published separately.⁴⁶ In addition, four studies reported growth pattern frequencies for chemo-naïve and chemotherapy-treated patients separately.^{13 29–31} In one study with two cohorts,²⁷ all patients had received cytotoxic therapy in combination with the anti-vascular endothelial growth

factor antibody bevacizumab, while in another study, the cohort receiving bevacizumab in addition to chemotherapy was analysed individually.¹³ Figure 4A shows the distribution of growth patterns stratified according to the administration of preoperative chemotherapy. Although there was substantial variation between studies with respect to histopathological analysis, which precluded quantitative synthesis, there were no obvious differences in overall growth pattern distribution across treatment groups (figure 4B). However, a decrease in the frequency of the pushing pattern was observed in patients treated with both bevacizumab and chemotherapy, likely due to differences in histologic classification²⁷ as discussed below.

Intralesional heterogeneity of CRLM growth patterns

The fact that some authors assessed desmoplasia/encapsulation independently of the other growth patterns indicated heterogeneity within single metastases. This is also reflected in the recent consensus guidelines, in which a cut-off >50% of the tumour-liver interface is considered defining the predominant growth pattern.¹⁸ Therefore, next we assessed how frequently heterogeneous patterns were reported. We found that in addition to the four studies in which the desmoplastic pattern was a separate parameter, a 'mixed' pattern was reported independently of the three main patterns in a further three studies,^{14 15 44} and independently of the desmoplastic and replacement patterns in a fourth.²⁸ Frequencies for a mixed pattern

Figure 3 Classification systems and reported frequencies of colorectal cancer liver metastases (CRLM) growth patterns. (A) Overall reported frequencies of CRLM growth patterns. Heterogeneous expressions used to describe growth patterns between studies were grouped by similarity with respect to their individual terms and associated descriptions into ‘consensus terms’ (related to figure 2). (B) Number of growth patterns considered in each study. Note that some studies regarded the presence/absence of a fibrotic capsule as a parameter independent of the histological growth patterns—that is, ‘desmoplastic’ metastases could be simultaneously classified as ‘pushing’ or ‘replacement’. ‘Mixed’ patterns are not included, as they do not define a specific category. (C) Percentage frequencies of reported growth patterns by study, according to consensus terms. For studies (in italics) in which a capsule was assessed independently, its frequency is represented in a separate bar. Note: In some studies, single metastases could not be classified by the reporting authors, in which case the bars do not add up to 100%. Although Terayama *et al*⁴² considered a total of four growth patterns the description of ‘sinusoidal’ was considered to closely represent the ‘replacement’ pattern in this specific study and counted as such. GP, growth pattern.

were 18.6%¹⁵ and 17.6%¹⁴ in two larger cohorts and 10%²⁸ and 41.4%⁴⁴ in two smaller ones. Intralesional heterogeneity was also reflected indirectly in some studies that did not quantify this feature, stating that heterogeneity was ‘uncommon’,³¹ or that ‘usually’ or ‘in most of the cases’, only one growth pattern was present.^{12 33}

Similar to the consensus guidelines, a recent study addressed intralesional heterogeneity by scoring the percentage of each pattern for every individual lesion.²⁷ Of note, the authors refined their own previously developed criteria,¹² as they observed that in some cases in which tumour cells seemed to directly replace hepatocytes, flattening of the surrounding liver plates—a characteristic of the pushing type—was also apparent.²⁷

Interlesional heterogeneity of CRLM growth patterns

Approximately half of all patients with CRLM present with more than one hepatic lesion at the time of diagnosis.^{45 47} Hence, an important question was whether interlesional heterogeneity was present and how it was

assessed. Various approaches were used: three studies included a statement that multiple lesions showed similar pathological features,^{12 40 43} while in others, quantitative differences in growth patterns between multiple lesions were not commonly reported. In studies with statements on multiple lesions, the largest metastasis (or the lesion with the largest tumour-liver interface) was most frequently used for growth pattern assessment.^{12 33 40 43} Given the lack of quantitative reporting, interlesional heterogeneity could not be analysed further for review purposes. However, one additional paper (not included in the eligible studies due to likely cohort overlap) provided a systematic analysis of interlesional heterogeneity in chemonaïve patients with multiple CRLM (n=24).⁴⁸ Applying a three-tier system for desmoplastic, pushing, and replacement patterns, and also considering mixed cases, the authors found that in 20 patients with a uniform growth pattern in a single metastasis, 12 had a single growth pattern in all metastases, while eight

A

B

Figure 4 Reported frequencies stratified according to preoperative chemotherapy. (A) Percentage frequencies of reported growth patterns by study, grouped according to treatment: no preoperative treatment, cytototoxic chemotherapy, or cytototoxic chemotherapy plus bevacizumab. For studies (in italics) in which the capsule was assessed independently, its frequency is represented in a separate bar. Studies that reported both treated and untreated patients are grouped and indicated with grey or white background. The total number of patients in each study cohort is given to the right of each bar. (B) Reported frequencies for the three treatment groups; lines indicate minimum and maximum, filled circle indicates median (frequency in %). Note: The mixed pattern was reported in one study only for chemo and bev-chemo groups. bev, bevacizumab; chemo, conventional cytototoxic chemotherapy.

had CRLM of more than one type. Overall, the authors concluded that the data suggested ‘... that the growth pattern of liver metastases is not a random phenomenon’.⁴⁸ Two studies reported data on repeated hepatic resections. Of note, the majority of recurring CRLMs showed the same growth pattern as in the first resection (n=5 and n=21, respectively).^{30 33}

Prognostic potential of growth pattern assessment

Among the eligible studies, a total of 17 investigated the prognostic impact of CRLM growth patterns (online supplementary table 2). One additional study¹⁵ reported recurrence risk specifically for a cohort included in a more recent study.¹³ One study reported two cohorts separately,²⁷ yielding a total of 19 different patient cohorts

Figure 5 Impact of main growth patterns on prognosis. First column: The desmoplastic pattern is characterised by a rim of fibrotic stroma (green) that separates tumour cells from the surrounding hepatocytes. Second column: In the replacement pattern, tumour cells (grey) invade along the liver cell plates, replacing the hepatocytes (yellow). Third column: In the pushing pattern, the liver plates adjacent to the metastases appear flattened (arrowheads); blue: central veins. (A) Dot plot of all studies reporting outcome for every growth pattern; one dot corresponds to one study; (B) as in (A), but only considering studies published prior to Food and Drug Administration's (FDA) approval of bevacizumab (indicated by thick line in online supplementary table 2). Note that some studies found effects for more than one pattern.

for analysis of outcome. The most commonly reported metrics were overall survival, disease-free survival, and disease recurrence.

However, reported outcome data across studies were not applicable to pooled quantitative analysis due to substantial heterogeneity in terminology, definitions of histopathological criteria, classification systems (two or three-tiered), independent assessment of the capsule, and different outcome metrics.

Nevertheless, descriptive analysis (figure 5A) showed that for 14 out of 17 cohorts (82.4%) in which the CRLM growth pattern was assessed, a statistically significant favourable outcome was reported for patients with desmoplastic CRLM. In eight out of 12 cohorts (66.7%) in which the pattern was assessed, a significantly unfavourable outcome for patients with a predominantly replacement-type CRLM was found. No study reported the opposite effects, that is, neither inferior outcome for

desmoplastic pattern nor beneficial outcome for replacement pattern CRLM was found in any of the cohorts. Two studies found no significant differences, and one out of 12 studies (8.3%) that considered this pattern showed unfavourable survival for patients with pushing-type CRLM.

It has recently been shown that survival of patients with desmoplastic CRLM compared with the replacement type was favourable only in patients receiving the anti-angiogenic antibody bevacizumab, while there was no difference in the cohort that did not receive the drug.²⁷ When focusing on articles published before the approval of bevacizumab by the US Food and Drug Administration (FDA) in 2004,^{49 50} we found that all six studies that considered the desmoplastic growth pattern reported a significantly better outcome for patients with this pattern, while three out of four studies that considered the replacement-type growth pattern found a

significantly poorer survival associated with replacement pattern CRLM (figure 5B); two of these studies found both effects.

DISCUSSION

In the earliest systematic description of CRLM growth patterns identified in this systematic analysis of the literature, Morino *et al* classified the tumour border of CRLM inspired by previous observations in hepatocellular carcinoma⁵¹; the authors distinguished between ‘sinusoidal’ (largely corresponding ‘replacement’, but also used as a term to describe a very rare pattern for CRLM in the consensus guidelines¹⁸) and ‘expansive’ (corresponding to ‘pushing’). They assessed ‘capsule formation’ as an independent feature.⁴⁴ This early description established the morphological framework, and modifications of the initial terminology have been followed in all studies included in this systematic review.

The rationale behind the need for routine reporting of CRLM growth patterns is at least twofold: on one hand, the patterns may be useful for prognostication and may aid treatment decisions²⁷; on the other hand, it is likely that understanding these distinct patterns of metastatic progression will provide important insights into the biological mechanisms that support tumour growth in the liver. To this end, Frentzas *et al* showed that microvessel co-option, besides providing vascular supply, renders metastases of the replacement type resistant to anti-angiogenic therapy.²⁷ Furthermore, the authors suggested an alternative approach for treating replacement-type metastases by suppressing cancer cell motility, which they achieved experimentally by knocking down the actin-related protein 2/3 complex. It is worth noting that several studies published before FDA approval of anti-angiogenic therapy found a favourable prognosis for patients with desmoplastic-type CRLM, suggesting that there are important mechanistic insights beyond differences in angiogenesis to be gained from the different growth patterns (figure 5B).

The most significant limitation of this systematic review is intrinsic to the studies analysed and highlights a major challenge of the field: Pronounced study heterogeneity—most importantly in classification systems and histopathological definitions as summarised in online supplementary table 1—precluded quantitative synthesis. Although formal meta-analysis was not possible, a high number of studies that assessed outcome concluded that the desmoplastic pattern is associated with a favourable prognosis. This was independent of the era in which the patient cohorts were treated and thus the data indicate that specific treatment regimens cannot sufficiently explain the positive prognostic effect of the desmoplastic pattern. In addition, more than one quarter of all studies found that the replacement pattern was associated with unfavourable prognosis, suggesting that distinguishing between the desmoplastic and replacement patterns and understanding the underlying mechanisms likely is of

highest impact for developing prognostic tools and treatment strategies.

As highlighted by our results, comparable data are essential for future quantification, and following common terminologies as well as growth pattern definitions is warranted. We suggest, in line with the recent consensus guidelines,¹⁸ the most frequently used terms, ‘desmoplastic’, ‘replacement’, and ‘pushing’. We hope that this review will contribute to routine pathological reporting of the histological growth patterns in CRLM.

Acknowledgements MG acknowledges grants from the Swedish Cancer Society and the Ruth and Richard Julin Foundation. The authors are grateful to Gun Brit Knutsson and Susanne Gustafsson at Karolinska Institutet University Library for their help with the literature search and to Rune Toftgård for comments on the manuscript. The authors thank Tobias Grönlund for help with the growth pattern illustrations and Sarah Lang for editing the manuscript.

Contributors CFM and MG designed the study, extracted and analysed the data and wrote the manuscript. BB contributed to the conceptualisation of the study, analysed the data upon consultation by CFM and MG and commented on the manuscript.

Funding This study was funded by the Swedish Cancer Society (Cancerfonden 2014/1376) and the Ruth and Richard Julin Foundation (2016juli46405 and 2015juli44263).

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The data generated during and/or analysed for the current study are available from the corresponding author (MG) upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

1. Siegel RL, Miller KD, Jemal A, *et al* CA Cancer J Clin 2016;2016:7–30.
2. O’Connell JB, Maggard MA, Cy K. Staging Colon Cancer Survival Rates With the New American Joint Committee on Cancer. *JNCI J Natl Cancer Inst* 2004;96:1420–5.
3. Wong SL, Mangu PB, Choti MA, *et al*. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. *J Clin Oncol* 2010;28:493–508.
4. Riihimäki M, Hemminki A, Sundquist J, *et al*. Patterns of metastasis in colon and rectal cancer. *Sci Rep* 2016;6:29765.
5. Nordlinger B, Van Cutsem E, Rougier P, *et al*. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. *Eur J Cancer* 2007;43:2037–45.
6. Adam R, de Gramont A, Figueras J, *et al*. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. *Cancer Treat Rev* 2015;41:729–41.
7. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. *Lancet* 1987;1:1303–6.
8. Compton C, Fenoglio-Preiser CM, Pettigrew N, *et al*. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. *Cancer* 2000;88:1739–57.
9. Karamitopoulou E, Zlobec I, Koelzer VH, *et al*. Tumour border configuration in colorectal cancer: proposal for an alternative scoring system based on the percentage of infiltrating margin. *Histopathology* 2015;67:464–73.
10. Zlobec I, Baker K, Minoo P, *et al*. Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups. *Cancer* 2009;115:4021–9.

11. Nagashima I, Oka T, Hamada C, *et al.* Histopathological prognostic factors influencing long-term prognosis after surgical resection for hepatic metastases from colorectal cancer. *Am J Gastroenterol* 1999;94:739–43.
12. Vermeulen PB, Colpaert C, Salgado R, *et al.* Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. *J Pathol* 2001;195:336–42.
13. Eefsen RL, Engelholm L, Willemoe GL, *et al.* Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab. *Int J Cancer* 2016;138:1777–84.
14. Van den Eynden GG, Bird NC, Majeed AW, *et al.* The histological growth pattern of colorectal cancer liver metastases has prognostic value. *Clin Exp Metastasis* 2012;29:541–9.
15. Eefsen RL, Vermeulen PB, Christensen IJ, *et al.* Growth pattern of colorectal liver metastasis as a marker of recurrence risk. *Clin Exp Metastasis* 2015;32:369–81.
16. Nielsen K, Rolff HC, Eefsen RL, *et al.* The morphological growth patterns of colorectal liver metastases are prognostic for overall survival. *Mod Pathol* 2014;27:1641–8.
17. The Royal College of Pathologists. Reporting proforma for liver resection - colorectal cancer metastasis (Appendix C5). <https://www.rcpath.org/resourceLibrary/liver-resection-colorectal-cancer-metastasis.html> (accessed 8 Jun 2017).
18. van Dam PJ, van der Stok EP, Teuwen LA, *et al.* International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. *Br J Cancer* 2017;117:1427.
19. Rhim AD, Oberstein PE, Thomas DH, *et al.* Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. *Cancer Cell* 2014;25:735–47.
20. Gerling M, Büller NV, Kirn LM, *et al.* Stromal Hedgehog signalling is downregulated in colon cancer and its restoration restrains tumour growth. *Nat Commun* 2016;7:12.
21. Mezheyeuski A, Bradic Lindh M, Guren TK, *et al.* Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. *Oncotarget* 2016;7:41.
22. Isella C, Terrasi A, Bellomo SE, *et al.* Stromal contribution to the colorectal cancer transcriptome. *Nat Genet* 2015;47:312–9.
23. Cunha SI, Bocci M, Lövdrot J, *et al.* Endothelial ALK1 is a therapeutic target to block metastatic dissemination of breast cancer. *Cancer Res* 2015;75:2445–56.
24. Whiting P, Rutjes AW, Reitsma JB, *et al.* The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Med Res Methodol* 2003;3:25.
25. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]; Table 8.5.a: The Cochrane Collaboration tool for assessing risk of bias. 2011. http://handbook.cochrane.org/chapter_8/table_8_5_a_the_cochrane_collaborations_tool_for_assessing.htm (accessed 16 Jun 2017).
26. Moher D, Liberati A, Tetzlaff J, *et al.* Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;339:b2535.
27. Frentzas S, Simoneau E, Bridgeman VL, *et al.* Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. *Nat Med* 2016;22:1294–302.
28. Siriwardana PN, Luong TV, Watkins J, *et al.* Biological and Prognostic Significance of the Morphological Types and Vascular Patterns in Colorectal Liver Metastases (CRLM): Looking Beyond the Tumor Margin. *Medicine* 2016;95:e2924.
29. Serrablo A, Paliogiannis P, Pulighe F, *et al.* Impact of novel histopathological factors on the outcomes of liver surgery for colorectal cancer metastases. *Eur J Surg Oncol* 2016;42:1268–77.
30. Brunner SM, Kesselring R, Rubner C, *et al.* Prognosis according to histochemical analysis of liver metastases removed at liver resection. *Br J Surg* 2014;101:1681–91.
31. Pinheiro RS, Herman P, Lupinacci RM, *et al.* Tumor growth pattern as predictor of colorectal liver metastasis recurrence. *Am J Surg* 2014;207:493–8.
32. Wiggins MG, Shahtahmassebi G, Malcolm P, *et al.* Extended pathology reporting of resection specimens of colorectal liver metastases: the significance of a tumour pseudocapsule. *HPB* 2013;15:687–94.
33. Nyström H, Naredi P, Berglund A, *et al.* Liver-metastatic potential of colorectal cancer is related to the stromal composition of the tumour. *Anticancer Res* 2012;32:5183–91.
34. Rajaganeshan R, Jayne DG, Malik HZ, *et al.* Biological characteristics and behaviour of putatively curatively resected colorectal liver metastases. *Eur J Surg Oncol* 2008;34:439–44.
35. Stessels F, Van den Eynden G, Van der Auwera I, *et al.* Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. *Br J Cancer* 2004;90:1429–36.
36. Terayama N, Matsui O, Ueda K, *et al.* Peritumoral rim enhancement of liver metastasis: hemodynamics observed on single-level dynamic CT during hepatic arteriography and histopathologic correlation. *J Comput Assist Tomogr* 2002;26:975–80.
37. Yamaguchi J, Komuta K, Matsuzaki S, *et al.* Mode of infiltrative growth of colorectal liver metastases is a useful predictor of recurrence after hepatic resection. *World J Surg* 2002;26:1122–5.
38. Weber JC, Nakano H, Bachellier P, *et al.* Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? *Am J Surg* 2001;182:81–8.
39. Lunevicius R, Nakanishi H, Ito S, *et al.* Clinicopathological significance of fibrotic capsule formation around liver metastasis from colorectal cancer. *J Cancer Res Clin Oncol* 2001;127:193–9.
40. Okano K, Yamamoto J, Kosuge T, *et al.* Fibrous pseudocapsule of metastatic liver tumors from colorectal carcinoma. *Cancer* 2000;89:267–75.
41. Ambiru S, Miyazaki M, Isono T, *et al.* Hepatic resection for colorectal metastases. *Diseases of the Colon & Rectum* 1999;42:632–9.
42. Terayama N, Terada T, Nakanuma Y. Histologic growth patterns of metastatic carcinomas of the liver. *Jpn J Clin Oncol* 1996;26:24–9.
43. Yamamoto J, Sugihara K, Kosuge T, *et al.* Pathologic support for limited hepatectomy in the treatment of liver metastases from colorectal cancer. *Ann Surg* 1995;221:74–8.
44. Morino T, Tanaka J, Tobe T. Clinico-pathological features of liver metastases from colorectal cancer in relation to prognosis. *Nihon Geka Hokan* 1991;60:154–64.
45. Nordlinger B, Sorbye H, Glimelius B, *et al.* Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. *Lancet Oncol* 2013;14:1208–15.
46. Rajaganeshan R, Prasad R, Guillou PJ, *et al.* The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases. *Br J Cancer* 2007;96:1112–7.
47. Tomlinson JS, Jarnagin WR, DeMatteo RP, *et al.* Actual 10-year survival after resection of colorectal liver metastases defines cure. *J Clin Oncol* 2007;25:4575–80.
48. Eefsen RL, Van den Eynden GG, Hoyer-Hansen G, *et al.* Histopathological growth pattern, proteolysis and angiogenesis in chemo-naïve patients resected for multiple colorectal liver metastases. *J Oncol* 2012;2012:1–12.
49. Hurwitz H, Fehrenbacher L, Novotny W, *et al.* Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004;350:2335–42.
50. Ferrara N, Hillan KJ, Gerber HP, *et al.* Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. *Nat Rev Drug Discov* 2004;3:391–400.
51. Nakashima T, Kojiro M, Kawano Y, *et al.* Histologic growth pattern of hepatocellular carcinoma: relationship to orcein (hepatitis B surface antigen)-positive cells in cancer tissue. *Hum Pathol* 1982;13:563–8.